- Ross Camidge, clinical lecturer in cancer therapeutics (drcamidge@talk21.com)1,
- Andrew Walker, senior lecturer in health economics2,
- James J Oliver, clinical lecturer in clinical pharmacology and therapeutics1,
- Fiona Nussey, clinical lecturer in medical oncology3,
- Simon Maxwell, senior lecturer in clinical pharmacology and therapeutics1,
- Duncan Jodrell, reader in oncology3,
- David J Webb, professor of clinical pharmacology and therapeutics1
- 1Clinical Pharmacology Unit, Western General Hospital, Edinburgh EH4 2XU,
- 2Robertson Centre for Biostatistics, University of Glasgow, Glasgow G12 8QQ,
- 3Edinburgh Cancer Centre, Western General Hospital
- Correspondence to: R Camidge
- Accepted 1 April 2005
How long someone has to live intuitively seems important in rationing decisions. Incorporating it into economic assessments, as described here, could make decisions fairer
Introduction
Explicit rationing—decisions not to fund certain treatments—has become a fact of life in many healthcare systems.1–4 Health economic assessments often underpin rationing decisions, although it remains unclear whether society's values are well reflected by the utilitarian approach of maximising the units of health attainable from available resources.5 6 Health economic assessments are used to determine the additional cost per unit of health gain for different treatment options. Cost effectiveness analysis is the most common method of assessment7 8 and, for life shortening conditions, primarily focuses on the additional cost per life year gained. We propose that prognosis without treatment is an important contextual modifier of life years gained in evaluating treatments for life shortening conditions. We present initial data supporting this hypothesis and describe resource allocation strategies that use this information.
Limitations of life years gained
Life years gained represent the extra life expectancy resulting from a treatment. By definition, the comparison is with the life expectancy associated with an established standard of care for the condition. Depending on the condition, the established standard of care may be interventional or supportive.
Using life years gained in health economic assessments has several problems. The first is that they are inapplicable to treatments that do not prolong life. Most of the other problems relate to the fact that a year of life in a particular clinical setting may not have the same value as a year of life in a different clinical setting.
QALYs and contextual modifiers
Initial attempts at improving the fairness of life years gained resulted in the development of quality adjusted life years (QALYs). In a QALY, each unit of time in a health state is weighted by both …
Sign in
Personal subscribers, sign in here:
Article access
Article access for 1 day
Purchase this article for £20 $30 €32*
The PDF version can be downloaded as your personal record
CiteULike
Connotea
Del.icio.us
Digg
Facebook
Reddit
Technorati
Twitter
Stumbleupon
Rapid responses
Latest Responses
Ethical considerations
Published 14 February 2012
Re: Diagnosis and management of Raynaud’s phenomenon
Published 14 February 2012
Re: Raised inflammatory markers
Published 14 February 2012
Re: Physical activity for cancer survivors: meta-analysis of randomised controlled trials
Published 14 February 2012
Smokefree cars in Wales: Laws are better
Published 14 February 2012
Most responses
Does anyone understand the government’s plan for the NHS? (17 responses)
Published 17 Jan 2012
Bad medicine: medical nutrition (15 responses)
Published 18 Jan 2012
Shared decision making: really putting patients at the centre of healthcare (8 responses)
Published 27 Jan 2012
Why legislation is necessary for my health reforms (8 responses)
Published 1 Feb 2012
How much of a social media profile can doctors have? (7 responses)
Published 23 Jan 2012